Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study
Status:
Completed
Trial end date:
2020-02-18
Target enrollment:
Participant gender:
Summary
This is a window of opportunity study for patients with resectable squamous cell carcinoma of
the oral cavity who are considered suitable for curative-intent surgical resection, with
pre-operative drugs, Sitravatinib and Nivolumab.